Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma

  • Leukemia. 2018 Feb;32(2):565-569. doi: 10.1038/leu.2017.309.
G Hu  1 ,  S Dasari  2 ,  Y W Asmann  3 ,  P T Greipp  1  4 ,  R A Knudson  4 ,  H K Benson  1 ,  Y Li  2 ,  B W Eckloff  4 ,  J Jen  1 ,  B K Link  5 ,  L Jiang  6 ,  J S Sidhu  7 ,  L E Wellik  8 ,  T E Witzig  8 ,  N N Bennani  8 ,  J R Cerhan  2 ,  R L Boddicker  1 ,  A L Feldman  1
Affiliations
  • 1. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • 2. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
  • 3. Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA.
  • 4. Medical Genome Facility, Mayo Clinic, Rochester, MN, USA.
  • 5. Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
  • 6. Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL, USA.
  • 7. Department of Pathology and Laboratory Medicine, United Health Services Hospitals, Johnson City/Binghamton, NY, USA.
  • 8. Division of Hematology, Mayo Clinic, Rochester, MN, USA.
PMID: 29026208 DOI: 10.1038/leu.2017.309